This review concluded that omega-3 polyunsaturated fatty acids significantly improved depressive symptoms in participants with mood disorders, clearly defined depression, or bipolar disorder. The dosage used did not change this effect significantly. Poor reporting of review methods and uncertainty about between-study differences mean that the reliability of the authors' conclusions is unclear.
Results of the review
Ten double-blind, placebo-controlled studies (329 participants) were included in the review.
The results showed there was a moderate antidepressant effect of omega-3 PUFAs in comparison with placebo (SMD 0.61, 95% CI: 0.21, 1.01, p=0.003; 10 studies). However, there was evidence of significant heterogeneity (p=0.004). The sensitivity analysis showed that none of the included studies strongly affected the positive effect of the treatment (data not presented).
Subgroup analysis of studies that examined clearly defined depression using HAM-D criteria showed a significant antidepressant effect of omega-3 PUFAs compared with placebo (SMD 0.69, 95% CI: 0.24, 1.13, p=0.002; 8 studies, 222 participants). However, there was again evidence of significant heterogeneity (p=0.03).
Further subgroup analysis showed a significant antidepressant effect of omega-3 PUFAs compared with placebo in participants with bipolar disorder (ES 0.69, 95% CI: 0.28, 1.0, p=0.0009; 2 studies, 67 participants). Subgroup analysis dividing studies by different dosage of eicosapentaenoic acid showed no statistically significant differences between the low-, medium-and high-dosage groups.
There was evidence of significant publication bias (p<0.025).
Authors' conclusions
Omega-3 PUFAs significantly improved depressive symptoms in participants with mood disorders, clearly defined depression, or bipolar disorder. The dose of eicosapentaenoic acid used did not significantly change the antidepressant effect. However, there was evidence of significant heterogeneity among the studies, as well as publication bias.
CRD commentary
Inclusion criteria were specified for the participants, intervention, outcomes and study design. Several relevant sources were searched, but the restriction to studies in English might have resulted in the loss of some relevant data and there was evidence of publication bias. The methods used to select studies and extract the data were not described, so it was not known whether any efforts were made to reduce errors and bias.
Study quality was not assessed, thus the results from these studies and any synthesis may not be reliable. The analyses seemed appropriate and statistical heterogeneity was assessed, although the source of the heterogeneity was not fully investigated. In addition, there was significant clinical heterogeneity between the studies. However, the authors did accept that their conclusions may be limited by heterogeneity and publication bias.
Incomplete reporting of review methods and uncertainty about between-study differences mean that the reliability of the authors' conclusions is uncertain.
